Minova Life Science

Minova life sciences - Pharmaceutical company

Diazero-M Tablets

COMPOSITION – Glimepiride IP 2mg + Metformin Hydrochloride IP 500 mg


  • Lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors.

• Claimed to be neutral with respect to body weight and weight reduction.

Safe and effective for use in the pediatric population.”


• First-line drug of choice for the treatment of type

• Decreases hyperglycemia primarily by suppressing glucose production by the liver.

Glimepiride/metformin combination therapy was more effective in glycemic control than metformin monotherapy and was well tolerated in type 2 diabetic patients.”

Glimipride/metformin demonstrated being more efficacious than glibenclamide/ metformin at reaching the glycemic control goals in patients with uncontrolled type 2 diabetes mellitus

Explore other products

Scroll to Top